Literature DB >> 2043575

Use of cyclosporin in the management of steroid dependent non-necrotising scleritis.

K N Hakin1, J Ham, S L Lightman.   

Abstract

Many patients with non-necrotising scleritis can be treated adequately with non-steroidal anti-inflammatory drugs or steroids. But, as many of them are young, treatment may present problems if they require high doses of steroids to control the scleral inflammation and then relapse when the dosage is reduced. Five such patients were treated with a combination of steroids and low-dose cyclosporin therapy, and in all cases the scleritis remained under control on a much lower dose of steroids than when steroids were used alone. Cyclosporin is therefore a useful drug in the management of younger patients dependent on high-dose steroids to control their scleral inflammation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2043575      PMCID: PMC1042378          DOI: 10.1136/bjo.75.6.340

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Doyne Memorial Lecture, 1982. The nature and the treatment of scleral inflammation.

Authors:  P G Watson
Journal:  Trans Ophthalmol Soc U K       Date:  1982-07

2.  Immunosuppressive therapy for external ocular inflammatory disease.

Authors:  C S Foster
Journal:  Ophthalmology       Date:  1980-02       Impact factor: 12.079

3.  Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation.

Authors:  H M Towler; P H Whiting; J V Forrester
Journal:  Eye (Lond)       Date:  1990       Impact factor: 3.775

4.  Necrogranulomatous keratitis associated with Wegener's granulomatosis and rheumatoid arthritis.

Authors:  D Sevel
Journal:  Am J Ophthalmol       Date:  1967-02       Impact factor: 5.258

5.  Cyclosporin therapy for severe scleritis.

Authors:  D Wakefield; P McCluskey
Journal:  Br J Ophthalmol       Date:  1989-09       Impact factor: 4.638

6.  Chlorambucil in Behçet's disease. A reappraisal.

Authors:  K F Tabbara
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079

7.  Treatment of intraocular inflammatory disease with cyclosporin A.

Authors:  R B Nussenblatt; A G Palestine; A H Rook; I Scher; W B Wacker; I Gery
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

8.  Renal histopathologic alterations in patients treated with cyclosporine for uveitis.

Authors:  A G Palestine; H A Austin; J E Balow; T T Antonovych; S G Sabnis; H G Preuss; R B Nussenblatt
Journal:  N Engl J Med       Date:  1986-05-15       Impact factor: 91.245

9.  Microscopical studies of necrotising scleritis. I. Cellular aspects.

Authors:  R D Young; P G Watson
Journal:  Br J Ophthalmol       Date:  1984-11       Impact factor: 4.638

  9 in total
  9 in total

Review 1.  Ophthalmic manifestations of rheumatologic disease: diagnosis and management.

Authors:  Carisa K Petris; Arghavan Almony
Journal:  Mo Med       Date:  2012 Jan-Feb

2.  Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial.

Authors:  Nirali Bhatt; Monica Dalal; William Tucker; Dominic Obiyor; Robert Nussenblatt; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2014-12-17       Impact factor: 5.258

3.  Use of orbital floor steroids in the management of patients with uniocular non-necrotising scleritis.

Authors:  K N Hakin; J Ham; S L Lightman
Journal:  Br J Ophthalmol       Date:  1991-06       Impact factor: 4.638

4.  Necrotising scleritis and connective tissue disease--three cases and a review.

Authors:  Sharmin Nizam; Annette Johnstone; Michael Green; Andrew Gough
Journal:  Clin Rheumatol       Date:  2008-12-04       Impact factor: 2.980

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Cells perpetuating the inflammatory response in scleritis.

Authors:  W Bernauer; P G Watson; B Daicker; S Lightman
Journal:  Br J Ophthalmol       Date:  1994-05       Impact factor: 4.638

7.  Infliximab for the treatment of active scleritis.

Authors:  H Nida Sen; Amit Sangave; Keri Hammel; Grace Levy-Clarke; Robert B Nussenblatt
Journal:  Can J Ophthalmol       Date:  2009-06       Impact factor: 1.882

8.  A case of nodular scleritis in association with Behcet's disease.

Authors:  H K Chang; E H Cho
Journal:  Korean J Intern Med       Date:  2001-03       Impact factor: 2.884

Review 9.  Management of noninfectious scleritis.

Authors:  Ahmad Abdel-Aty; Akash Gupta; Lucian Del Priore; Ninani Kombo
Journal:  Ther Adv Ophthalmol       Date:  2022-01-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.